1. Latest News
  2. Submit Press Release

Cambridge Healthtech Institute Presents the 3rd Annual Oncology Clinical Trials Conference

CHI’s Oncology Clinical Trials: Bringing Effective and Safe Cancer Therapy to Patient takes place Feb. 13-15, 2013 at the Moscone in San Francisco, CA. This conference is part of the many program options available at the Molecular Med TRI-CON 2013.

Oct. 4, 2012 - PRLog -- Needham Ma - Attendees of this meeting will hear about how the recent breakthroughs in understanding the molecular biology of cancer have led to an unprecedented number of new targets in oncology drug development. There are more cancer drugs in the research pipeline than any other type of therapy, corresponding directly with the number of oncology clinical trials. Why do phase III clinical trials in oncology fail so often? One simple answer does not exist to this critically important question. Success of an oncology trial depends on many factors: scientific, organizational, biostatistical, regulatory, ethical and economical.  The second annual Oncology Clinical Trials is designed to provide a comprehensive coverage of many of these components as well as present case studies of successful clinical trials.

Keynote addresses include:

-Personalized Oncology – Fulfilling the Promise for Today's Patients

In honor of the 20th anniversary of the Molecular Medicine Tri-Conference, CHI and Cancer Commons will present a plenary panel on Personalized Oncology. Innovations such as NGS and The Cancer Genome Atlas have revealed that cancer comprises hundreds of distinct molecular diseases. Early clinical successes with targeted therapies suggest that cancer might one day be managed as a chronic disease using an evolving cocktail of drugs.Representing all five conference channels, Diagnostics, Therapeutics, Clinical, Informatics, and Cancer, a panel of experts will lead a highly interactive exploration of what it will take to realize this vision in the near future.

-Challenges in Understanding Resistance to Targeted Therapies
Jamey Skillings, M.D., Vice President, Global Medical Affairs, Pfizer  

This presentation will describe the evolution of clinical and molecular data which describe resistance to Xalkori. Case examples from this program and other targeted therapies will be used to discuss how evidence can be developed to support treatment decisions after RECIST progression.

-Emerging Technologies & Industry Perspectives

This session features a series of presentations on emerging and hot technologies in diagnostics, drug discovery & development, informatics, and oncology. Interactive Q&A discussion with the audience will be included

-Novel Strategies in Oncology Clinical Development
Eric Rubin, M.D., Vice President, Clinical Research Oncology, Merck

As part of the Molecular Med TRI-CON 2013, attendees have access to a partnering forum, 5 symposia, 18 short courses, and 12 core programs. The event attracts more than 3,000 attendees and provides attendees an opportunity to interact with each other in the shared exhibit/poster hall, plenary keynotes and social functions.

Early registration discounts are available until October 19th, 2013.  For complete event details visit: http://www.triconference.com/cct

To inquire about sponsoring and/or exhibiting, contact Jon Stroup, 781-972-5483, jstroup@healthtech.com.

Writers and editors are encouraged to attend. To request a press pass, contact Lisa Scimemi at lscimemi@healthtech.com.

About Cambridge Healthtech Institute (www.chicorporate.com)
Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

--- End ---

Click to Share

Contact Email:
***@healthtech.com Email Verified
Source:Cambridge Healthtech Institute
Location:Needham - Massachusetts - United States
Industry:Biotech, Science
Tags:Clinical Trials, Oncology, Biotech, Big Pharma, Oncology Clinical Development
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “


Trending News...

Like PRLog?
Click to Share